Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety
In time, prescription of insulin therapy (IT) becomes inevitable for many patients with type 2 diabetes mellitus (DM) to achieve and maintain the target hypoglycemic range.According to the current guidelines, the addition of basal insulin to glucose-lowering therapy in patients with insufficient con...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-09-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/6355 |
| _version_ | 1797841777643749376 |
|---|---|
| author | E. V. Biryukova M. V. Shinkin O. M. Mikheeva |
| author_facet | E. V. Biryukova M. V. Shinkin O. M. Mikheeva |
| author_sort | E. V. Biryukova |
| collection | DOAJ |
| description | In time, prescription of insulin therapy (IT) becomes inevitable for many patients with type 2 diabetes mellitus (DM) to achieve and maintain the target hypoglycemic range.According to the current guidelines, the addition of basal insulin to glucose-lowering therapy in patients with insufficient control of type 2 diabetes, gradual titration of its dose in accordance with a fasting blood glucose level is an effective and safe method for initiating IT. The properties of modern long-acting insulin analogues are considered. Glargine 300 U/ml is a modern analogue of long-acting insulin that is intended to be used once a day. The glargine molecule forms the basis of the drug. Increasing the concentration of glargine per volume unit and formation of a smaller subcutaneous depot led to a change in the pharmacokinetic properties of the drug. Glargine 300 IU/ml provides a more stable, long-term, predictable action with low glycemic variability as compared with glargine 100 IU/ml, which reduces the risk of hypoglycemia. The sugar-reducing efficacy and safety of insulin glargine 300 U/ml as evidenced by the findings of the international clinical phase III EDITION studies are discussed. Insulin glargine 300 U/ml showed a similar decrease in HbA1c levels compared to insulin glargine 100 U/ml with an improved safety profile (lower risk of developing episodes of confirmed or severe hypoglycemia at all times of the day, including the nighttime) and a less pronounced effect on the body weight of patients with type 2 diabetes. The efficacy and safety of the use of glargine 300 U/ml has been confirmed in type 2 diabetes patients with chronic kidney disease and the elderly. In the BRIGHT study, glargine 300 U/ml showed comparable glycemic control when it is being compared. |
| first_indexed | 2024-04-09T16:36:22Z |
| format | Article |
| id | doaj.art-94bb57dd83194fa4bba786b81eaf607a |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:36:22Z |
| publishDate | 2021-09-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-94bb57dd83194fa4bba786b81eaf607a2023-04-23T06:56:53ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902021-09-0101224625510.21518/2079-701X-2021-12-246-2555733Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safetyE. V. Biryukova0M. V. Shinkin1O. M. Mikheeva2Yevdokimov Moscow State University of Medicine and DentistryYevdokimov Moscow State University of Medicine and DentistryYevdokimov Moscow State University of Medicine and DentistryIn time, prescription of insulin therapy (IT) becomes inevitable for many patients with type 2 diabetes mellitus (DM) to achieve and maintain the target hypoglycemic range.According to the current guidelines, the addition of basal insulin to glucose-lowering therapy in patients with insufficient control of type 2 diabetes, gradual titration of its dose in accordance with a fasting blood glucose level is an effective and safe method for initiating IT. The properties of modern long-acting insulin analogues are considered. Glargine 300 U/ml is a modern analogue of long-acting insulin that is intended to be used once a day. The glargine molecule forms the basis of the drug. Increasing the concentration of glargine per volume unit and formation of a smaller subcutaneous depot led to a change in the pharmacokinetic properties of the drug. Glargine 300 IU/ml provides a more stable, long-term, predictable action with low glycemic variability as compared with glargine 100 IU/ml, which reduces the risk of hypoglycemia. The sugar-reducing efficacy and safety of insulin glargine 300 U/ml as evidenced by the findings of the international clinical phase III EDITION studies are discussed. Insulin glargine 300 U/ml showed a similar decrease in HbA1c levels compared to insulin glargine 100 U/ml with an improved safety profile (lower risk of developing episodes of confirmed or severe hypoglycemia at all times of the day, including the nighttime) and a less pronounced effect on the body weight of patients with type 2 diabetes. The efficacy and safety of the use of glargine 300 U/ml has been confirmed in type 2 diabetes patients with chronic kidney disease and the elderly. In the BRIGHT study, glargine 300 U/ml showed comparable glycemic control when it is being compared.https://www.med-sovet.pro/jour/article/view/6355hba1cintensification of hypoglycemic therapyinsulin analogueshypoglycemiaglargine 300 u/ml |
| spellingShingle | E. V. Biryukova M. V. Shinkin O. M. Mikheeva Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety Медицинский совет hba1c intensification of hypoglycemic therapy insulin analogues hypoglycemia glargine 300 u/ml |
| title | Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety |
| title_full | Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety |
| title_fullStr | Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety |
| title_full_unstemmed | Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety |
| title_short | Long-acting insulin analogue in the treatment of type 2 diabetes mellitus: emphasis on proven efficacy and safety |
| title_sort | long acting insulin analogue in the treatment of type 2 diabetes mellitus emphasis on proven efficacy and safety |
| topic | hba1c intensification of hypoglycemic therapy insulin analogues hypoglycemia glargine 300 u/ml |
| url | https://www.med-sovet.pro/jour/article/view/6355 |
| work_keys_str_mv | AT evbiryukova longactinginsulinanalogueinthetreatmentoftype2diabetesmellitusemphasisonprovenefficacyandsafety AT mvshinkin longactinginsulinanalogueinthetreatmentoftype2diabetesmellitusemphasisonprovenefficacyandsafety AT ommikheeva longactinginsulinanalogueinthetreatmentoftype2diabetesmellitusemphasisonprovenefficacyandsafety |